In Vitro Activity of HR 756, a New Cephalosporin, Against Neisseria gonorrhoeae

mentioning

confidence: 99%

Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas

Murray¹

1980

“…and has activity in vitro against aminoglycoside-resistant gram-negative rods (10, 11, 15; Hamilton, Engle and Schleupner, manuscript in preparation). Additionally, for both beta-lactamase-positive and negative strains of H. influenzae and N. gonorrhoeae, cefotaxime has been shown to be much more active than currently available cephalosporins and, with the exception of Bacteroides fragilis, is at least equivalent to other cephalosporins in its anaerobic spectrum of activity (1,4,11,12,16,18).…”

Section: Discussionmentioning

confidence: 99%

Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections

Schleupner¹,

Engle²

1982

A clinical trial was designed to evaluate the efficacy and safety of cefotaxime, a new semisynthetic, broad-spectrum cephalosporin, in the therapy of communityand hospital-acquired pneumonias. Thirty-nine males (mean age, 65 years) were treated for 41 episodes of pneumonia. Only five patients did not have a serious underlying disease; 15 had two or more significant disorders. Sixty-six percent of these pneumonias were due to Streptococcus pneumoniae or Haemophilus influenzae. The minimal inhibitory concentrations for all bacterial isolates ranged from 0.008 to 4 ,ug/ml. Peak serum cefotaxime levels during therapy ranged from 12 to 124 ,ug/ml 1 h after a 1-g dose. Satisfactory bacteriological and clinical responses were observed in 85% of the cases. Four episodes of pulmonary superinfections due to cefotaxime-resistant gram-negative bacilli were noted, each in a patient being mechanically ventilated. Pseudomonas was involved in each of these superinfections, and three were fatal. No serious toxicity or adverse reaction to cefotaxime was seen. The results of this study suggest that cefotaxime is an effective and well-tolerated new cephalosporin antimicrobial agent for the therapy of pneumonia due to susceptible organisms.

“…It was noted to be more active than a variety of other antimicrobial agents in vitro on a per-weight basis (8). The minimum inhibitory concentration of cefotaxime remained the same (c0.004 jLg/ml) whether 8-lactamase was produced or not (1).…”

mentioning

confidence: 88%

“…,8-lactamase (1,8). It was noted to be more active than a variety of other antimicrobial agents in vitro on a per-weight basis (8).…”

mentioning

confidence: 99%

Treatment of gonorrhea: comparison of cefotaxime and penicillin

Simpson¹,

Khan²,

Siddiqui³

et al. 1981

Ninety-seven patients with 118 sites infected with Neisseria gonorrhoeae were treated with a single dose of either procaine penicillin G (4.8 x 10(6) U) or cefotoxime (1.0 g) intramuscularly. Only the penicillin group took 1 g of probenecid orally. The numbers of infected sites in each treatment group were as follows: penicillin-urethra, 37; rectum, 9; cervix, 8; and pharynx, 4; cefotaxime-urethra, 42; rectum, 9; cervix, 5; and pharynx, 4. The cure rates in each treatment group were 100%. No adverse reactions were noted in either group. beta-Lactamase-positive N. gonorrhoeae strains were not found. Ninety-five percent of clinical isolates were inhibited by less than or equal to 0.007 micrograms of cefotaxime and less than or equal to 0.25 micrograms of penicillin per ml. In this study cefotaxime was as effective as procaine penicillin in the treatment of uncomplicated gonorrhea.